Stoke Therapeutics (STOK) Aktievy
Stoke Therapeutics, Inc. bedriver utveckling av behandlingar för allvarliga genetiska sjukdomar genom att uppreglera proteinuttryck. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
STOK Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Stoke Therapeutics, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$29.30 |
| 52 veckors högsta | US$40.22 |
| 52 veckors lägsta | US$12.25 |
| Beta | 1.18 |
| 1 månads förändring | -8.44% |
| 3 månaders förändring | -13.08% |
| 1 års förändring | 123.66% |
| 3 års förändring | 362.88% |
| 5 års förändring | 2.34% |
| Förändring sedan börsintroduktionen | 14.59% |
Senaste nyheter och uppdateringar
Seeking Alpha • Jul 19
Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch
Summary Stoke Therapeutics remains a speculative BUY, with a compelling disease-modifying approach for Dravet Syndrome and a robust RNA-based platform. Its Phase 3 EMPEROR trial for zorevunersen is now fully enrolled; top-line results expected in H2 2027, with week 28 data due late December. STOK’s $343.5M cash, milestone-rich Biogen and Acadia partnerships, and manageable burn rate provide financial runway through key catalysts. Goldman Sachs projects $44 PT, $1.5B peak sales for zorevunersen and a 75% probability of success, underlining the biotech's strong upside potential. Read the full article on Seeking Alpha
Uppdatering av berättelse • Jul 10
STOK: Phase 3 Dravet Data And NDA Timeline Will Drive Upside
Analysts have raised their fair value estimate for Stoke Therapeutics from $39.00 to $60.00, citing updated assumptions related to revenue growth, profitability, and a lower projected future P/E multiple. What’s in the News for Stoke Therapeutics Stoke Therapeutics has completed enrollment of 162 patients in the Phase 3 EMPEROR study of zorevunersen in Dravet syndrome.Recent updates
Seeking Alpha • Jul 19
Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch
Summary Stoke Therapeutics remains a speculative BUY, with a compelling disease-modifying approach for Dravet Syndrome and a robust RNA-based platform. Its Phase 3 EMPEROR trial for zorevunersen is now fully enrolled; top-line results expected in H2 2027, with week 28 data due late December. STOK’s $343.5M cash, milestone-rich Biogen and Acadia partnerships, and manageable burn rate provide financial runway through key catalysts. Goldman Sachs projects $44 PT, $1.5B peak sales for zorevunersen and a 75% probability of success, underlining the biotech's strong upside potential. Read the full article on Seeking AlphaUppdatering av berättelse • Jul 10
STOK: Phase 3 Dravet Data And NDA Timeline Will Drive Upside
Analysts have raised their fair value estimate for Stoke Therapeutics from $39.00 to $60.00, citing updated assumptions related to revenue growth, profitability, and a lower projected future P/E multiple. What’s in the News for Stoke Therapeutics Stoke Therapeutics has completed enrollment of 162 patients in the Phase 3 EMPEROR study of zorevunersen in Dravet syndrome.
Uppdatering av berättelse • Jun 26
None
Analysts have lifted their price target for Stoke Therapeutics from $34.25 to $45.10, citing updated assumptions around revenue growth, profitability, and a lower projected future P/E multiple as key drivers of the change. What’s in the News for Stoke Therapeutics No recent company specific news for Stoke Therapeutics was identified in the provided sources.Analysartikel • May 11
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results
As you might know, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just kicked off its latest quarterly results with some very...
Ny berättelse • May 11
Phase III Trial And Payer Risks Will Shape Dravet Treatment Prospects
Catalysts About Stoke Therapeutics Stoke Therapeutics is a biotechnology company focused on RNA-based medicines, including zorevunersen for Dravet syndrome. What are the underlying business or industry changes driving this perspective?Analysartikel • Jan 12
Newsflash: Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Have Been Trimming Their Revenue Forecasts
The analysts covering Stoke Therapeutics, Inc. ( NASDAQ:STOK ) delivered a dose of negativity to shareholders today, by...Analysartikel • Dec 05
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry
Despite an already strong run, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have been powering on, with a gain of...Analysartikel • Oct 09
Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 39%
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 39% gain in the last month...Analysartikel • Aug 25
Improved Revenues Required Before Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock's 49% Jump Looks Justified
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 49% gain in the last month...Analysartikel • Aug 15
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Could Be 25% Above Their Intrinsic Value Estimate
NasdaqGS:STOK 1 Year Share Price vs Fair Value Explore Stoke Therapeutics's Fair Values from the Community and select...Analysartikel • May 20
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders would be excited to see that the share price has had a great...Analysartikel • Apr 16
Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be
Market forces rained on the parade of Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders today, when the analysts...Analysartikel • Apr 05
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
To the annoyance of some shareholders, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares are down a considerable 27% in...Analysartikel • Feb 26
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Feb 16
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
Summary Stoke Therapeutics' RNA-based treatments for severe neurological and ophthalmic disorders, particularly zorevunersen for Dravet syndrome, show potential for long-term value beyond a single drug. Financials reveal high R&D spending and cash burn, but revenue growth from Acadia Pharmaceuticals collaboration suggests early monetization and potential non-dilutive funding. The Phase 3 EMPEROR study for zorevunersen is critical, with regulatory alignment and promising early data, but execution and long-term safety monitoring remain challenges. Stoke's broader pipeline, including treatments for SYNGAP1-related disorders, Rett syndrome, and Autosomal Dominant Optic Atrophy, could expand its market potential if RNA modulation proves broadly effective. Read the full article on Seeking AlphaAnalysartikel • Nov 08
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just released its third-quarter report and things are looking bullish. Results...Analysartikel • Nov 06
Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Sep 07
Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
Summary STOK's zorevunersen shows strong efficacy in reducing seizures but has safety concerns, particularly elevated CSF protein levels, needing further monitoring. Dravet Syndrome market potential is significant, with 35,000 patients in key regions and existing treatments costing up to $96,000 annually. STOK has a solid cash runway for 7-8 quarters, with a Phase 3 trial expected to start soon, aiming for topline data by mid-2026. Despite recent stock gains, I may consider investing when Phase 3 trial enrollment is announced, given the promising genetic approach to Dravet Syndrome. Read the full article on Seeking AlphaAktieägarnas avkastning
| STOK | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | 0.9% | -1.3% | -1.0% |
| 1Y | 123.7% | 29.0% | 14.7% |
Avkastning vs industri: STOK översteg US Biotechs branschen som gav 29 % under det senaste året.
Avkastning vs Marknaden: STOK översteg US marknaden som gav 14.7 % under det senaste året.
Prisvolatilitet
| STOK volatility | |
|---|---|
| STOK Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: STOK har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: STOK s veckovolatilitet ( 6% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2014 | 170 | Ian Smith | www.stoketherapeutics.com |
Stoke Therapeutics, Inc. utvecklar behandlingar för allvarliga genetiska sjukdomar genom att uppreglera proteinuttryck. Bolaget använder sin patentskyddade TANGO-metod (Targeted Augmentation of Nuclear Gene Output) för att utveckla antisens-oligonukleotider (ASO) som selektivt återställer proteinnivåerna. Bolagets ledande produktkandidater inkluderar STK-002, som befinner sig i kliniska fas 1-studier för behandling av autosomal dominant optisk atrofi; och Zorevunersen (STK-001), ett nytt läkemedel för behandling av Dravets syndrom, utvärderas i kliniska fas 3-studier.
Stoke Therapeutics, Inc. Sammanfattning av grunderna
| STOK grundläggande statistik | |
|---|---|
| Börsvärde | US$1.82b |
| Vinst(TTM) | -US$169.77m |
| Intäkter(TTM) | US$32.08m |
56.9x
P/S-förhållande-10.7x
P/E-förhållandeÄr STOK övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| STOK resultaträkning (TTM) | |
|---|---|
| Intäkter | US$32.08m |
| Kostnad för intäkter | US$0 |
| Bruttovinst | US$32.08m |
| Övriga kostnader | US$201.85m |
| Intäkter | -US$169.77m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -2.73 |
| Bruttomarginal | 100.00% |
| Nettovinstmarginal | -529.20% |
| Skuld/egenkapitalförhållande | 0% |
Hur har STOK utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/26 23:58 |
| Aktiekurs vid dagens slut | 2026/07/24 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Stoke Therapeutics, Inc. bevakas av 22 analytiker. 12 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Thomas Shrader | BTIG |
| Michelle Gilson | Canaccord Genuity |